MUK eight 方案:伊沙佐米联合环磷酰胺和地塞米松对比 CD 治疗来那度胺和硼替佐米治疗后复发的 RRMM 的随机 II 期试验
MUK eight 是一项随机、对照、开放、平行组、多中心 II 期试验,招募经沙利度胺、来那度胺和蛋白酶体抑制剂治疗后复发的 RRMM 患者,主要评估 ICD 相比 CD 能否改善无进展生存期(PFS),次要目标比较毒性和成本效果,并设探索性交叉阶段。
要点
- ICD 对比 CD 用于沙利度胺、来那度胺和蛋白酶体抑制剂治疗后复发的 RRMM 患者。
- 主要终点为无进展生存期(PFS),次要终点包括毒性谱和成本效果。
- CD 组按 IMWG 标准确认进展后可交叉接受 ICD,探索 PFS2 和 PFS Switch。
核心结论
- 该试验旨在评估 ICD 相比 CD 是否改善经沙利度胺、来那度胺和蛋白酶体抑制剂治疗后复发的 RRMM 患者的 PFS。
研究设计与样本
- MUK eight 为随机、对照、开放、平行组、多中心 II 期试验,招募经沙利度胺、来那度胺和蛋白酶体抑制剂治疗后复发的 RRMM 患者。
关键数值与推荐
- 主要终点为 PFS;次要终点包括毒性谱、两种治疗的活性和成本效果。
- CD 组患者按 IMWG 标准出现疾病进展且经两名 TMG 临床成员确认后可交叉接受 ICD。
- 交叉阶段为探索性,评估从随机化至第二次疾病进展的 PFS2 及从交叉至第二次疾病进展的 PFS Switch。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple myeloma is a plasma cell tumour with approximately 5500 new cases in the UK each year. Ixazomib is a next generation inhibitor of the 20S proteasome and is thought to be an effective treatment for those who have relapsed from bortezomib. The combination of cyclophosphamide and dexamethasone (CD) is a recognised treatment option for patients with relapsed refractory multiple myeloma (RRMM) who have relapsed after treatment with bortezomib and lenalidomide, whilst also often being combined with newer proteasome inhibitors. The most apparent combination for ixazomib is therefore with CD. METHODS: MUK eight is a randomised, controlled, open, parallel group, multi-centre phase II trial that will recruit patients with RRMM who have relapsed after treatment with thalidomide, lenalidomide, and a proteasome inhibitor. The primary objective of the trial is to evaluate whether ixazomib in combination with cyclophosphamide and dexamethasone (ICD) has improved clinical activity compared to CD in terms of progression-free survival (PFS). Secondary objectives include comparing toxicity profiles and the activity and cost-effectiveness of both treatments. Since opening, the trial has been amended to allow all participants who experience disease progression (as per the IMWG criteria) on the CD arm to subsequently switch to receive ICD treatment, once progression has been confirmed with two clinical members of the Trial Management Group (TMG). This 'switch' phase of the study is exploratory and will assess second progression-free survival measured from randomisation to second disease progression (PFS2) and progression-free survival from the point of switching to second disease progression (PFS Switch) in participants who switch from CD to ICD treatment. DISCUSSION: Development of ixazomib offers the opportunity to further investigate the value of proteasome inhibition through oral administration in the treatment of RRMM. Previous studies investigating the safety and efficacy of ICD in patients with RRMM demonstrate a toxicity profile consistent with ixazomib in combination with lenalidomide and dexamethasone, whilst the combination showed possible activity in RRMM patients. Further investigation of the anti-tumour effect of this drug in RRMM patients is therefore warranted, especially since no trials comparing CD with ICD have been completed at present. TRIAL REGISTRATION: ISRCTN number: ISRCTN58227268 . Registered on 26 August 2015.
引用
- Hinsley S, Walker K, Sherratt D, et al. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials. 2020. PMID: 33008427. doi:10.1186/s13063-020-04739-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。